United Therapeutics (NASDAQ:UTHR) is one of today's biggest movers, down 2.1% to $65.57. The Dow is trading fractionally higher to 15,261 and the S&P is currently trading fractionally higher to 1,645.
United Therapeutics (NASDAQ:UTHR) is currently priced 10.4% above its average consensus analyst price target of $58.78. The stock should discover initial support at its 50-day moving average (MA) of $64.26 and subsequent support at its 200-day MA of $57.05.
United Therapeutics share prices have moved between a 52-week high of $70.74 and a 52-week low of $36.55 and are now trading 79% above that low price at $65.57 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has advanced 0.7%.
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.